Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage biopharmaceutical company focused on the PI3 kinase pathway in oncology and inflammatory disease, closed a $30M Series B financing. Participants include Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners.